Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Helen Rubenstein, Vice President of Investor Relations and Communications. Please go ahead. Good afternoon, and thank you for joining Numora Therapeutics' first quarter 2025 financial results conference call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at numoratx.com, where you can find the press release related to today's call. With me from Numora are Chief Executive Officer Paul Burns, President Josh Pinto, Chief Operating and Development Officer Bill Arora, and Chief Financial Officer Mike Milligan. I'd like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional detail. With that, I'll now turn the call over to Paul. Thanks, Helen. Good afternoon, everyone, and thank you for joining us. At Numora, we believe the greatest medical challenge of our generation is the global brain disease crisis. This affects upwards of 1.5 billion people and causes a severe impact on quality of life, not only for patients, but also their families and society at large. Despite a number of approved therapies, there is a significant outstanding unmet need for safe and effective treatment options to alleviate the burdens of these diseases. When we founded Newmora, it was wi...